N,3-Dimethylbut-3-enamide | 63364-69-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,3-Dimethylbut-3-enamide
• 英文别名: N,3-dimethylbut-3-enamide
• CAS: 63364-69-2
• 化学式: C₆H₁₁NO
• 分子量: 113.16
• InChiKey: SIMHRQGBZOQZTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：Obrecht Daniel

  公开号：US20120270881A1

  公开（公告）日：2012-10-25

  Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y 1 , as modulators of the serotonin receptor of subtype 5-HT 2B , as blockers of the voltage-gated potassium channel K v 1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.

  具有结构限制的、空间定义的12-30环的大环系统Ia和Ib由三个不同的分子部分构成：模板A、构象调节剂B和桥C。这些大环Ia和Ib可以通过并行合成或溶液中或固相上的组合化学来轻松制备。它们被设计用于与各种特定的生物靶标类相互作用，例如对G蛋白偶联受体（GPCRs）、离子通道和信号转导途径的激动或拮抗活性。特别地，这些大环作为莫蒂林受体的拮抗剂、FP受体和嘌呤受体P2Y1的调节剂、5-HT2B亚型的5-羟色胺受体的调节剂、电压门控钾通道Kv1.3的阻断剂以及β-连环蛋白依赖的“经典”Wnt途径的抑制剂。因此，它们显示出作为各种疾病药物的巨大潜力。
• Hepatitis C inhibitor peptide analogs
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040224900A1

  公开（公告）日：2004-11-11

  Compounds of formula (I): 1 wherein B, Y, R 3 , R 24 , R 2 , R 1 and R C are defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

  式（I）的化合物：其中B、Y、R3、R24、R2、R1和Rc在此处被定义。这些化合物可用作HCV NS3蛋白酶的抑制剂。
• 4-ACYLAMINOPYRAZOLE DERIVATIVES
  申请人：Sankyo Company, Limited

  公开号：EP1329160A2

  公开（公告）日：2003-07-23

  A 4-acylaminopyrazole derivative represented by the following general formula: wherein R1 is a hydrogen atom, an optionally substituted C1-C16 alkyl group or the like,    R2 and R3 are independently a hydrogen atom, a halogen atom, an optionally substituted C1-C6 alkyl group or the like, R4 is a hydrogen atom, a C1-C6 alkyl group or a cyano group, Z is an oxygen atom or a sulfur atom, Ar is an optionally substituted C6-C14 aryl group or an optionally substituted 5-6 membered unsaturated heterocyclic group, B is a hydrogen atom, a halogen atom, an optionally substituted C1-C16 alkyl group or the like.

  由以下通式代表的 4-酰氨基吡唑衍生物： 其中 R1 是氢原子、任选取代的 C1-C16 烷基或类似基团、 R2 和 R3 独立地为氢原子、卤素原子、任选取代的 C1-C6 烷基或类似基团、 R4 是氢原子、C1-C6 烷基或氰基、 Z 是氧原子或硫原子、 Ar 是任选取代的 C6-C14 芳基或任选取代的 5-6 位元不饱和杂环基团、 B 是氢原子、卤素原子、任选取代的 C1-C16 烷基或类似基团。
• CONJUGATES OF CYSTEINE ENGINEERED ANTIBODIES
  申请人：ImmunoGen, Inc.

  公开号：EP3769787A1

  公开（公告）日：2021-01-27

  The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.

  本发明涉及新型细胞结合剂-细胞毒剂共轭物，其中细胞结合剂（CBA）通过一个工程Cys与细胞毒剂共价连接，例如重链CH3结构域中的工程Cys，其位置与抗体CBA上的EU/OU编号位置442（或C442）相对应。本发明还提供了制备本发明共轭物的方法。本发明进一步提供了使用本发明共轭物抑制哺乳动物异常细胞生长或治疗增殖性疾病的组合物和方法。
• POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTALLINE POLYMER, AND OPTICAL ANISOTROPIC ARTICLE
  申请人：Sakamoto Kei

  公开号：US20100258764A1

  公开（公告）日：2010-10-14

  A polymerizable liquid crystal compound shown by the following formula (I), a polymerizable liquid crystal composition that includes the polymerizable liquid crystal compound and a chiral compound polymerizable with the polymerizable liquid crystal compound, a liquid crystalline polymer obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and an optical anisotropic article that includes the liquid crystalline polymer. The polymerizable liquid crystal compound shows a liquid crystal phase over a wider temperature range, is chemically stable, can be inexpensively produced, and has a wide selective reflection wavelength band Δλ (i.e., a large value Δn). The polymerizable liquid crystal composition includes the polymerizable liquid crystal compound, the liquid crystalline polymer is obtained by polymerizing the polymerizable liquid crystal compound or the polymerizable liquid crystal composition, and the optical anisotropic article includes the liquid crystalline polymer. wherein Y 1 to Y 6 represent —O—, —O—C(═O)—, —C(═O)—O—, or the like, G 1 and G 2 represent divalent aliphatic groups having 1 to 20 carbon atoms, Z 1 and Z 2 represent an alkenyl group having 2 to 10 carbon atoms or the like, A 1 and A 2 represent divalent organic groups A having 1 to 30 carbon atoms, X 1 to X 8 represent a hydrogen atom or the like, and a and b represent 0 or 1.